Предиктивная и прогностическая роль инфильтрирующих опухоль лимфоцитов (TILs) при раннем трижды негативном раке молочной железы


DOI: https://dx.doi.org/10.18565/pharmateca.2022.7.37-42

Абдулаева Ш.Р., Семиглазова Т.Ю., Артемьева А.С., Кудайбергенова А.Г., Шарашенидзе С.М., Целуйко А.И., Палтуев Р.М., Семиглазов В.В., Криворотько П.В., Семиглазов В.Ф.

1) Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова, Санкт-Петербург, Россия; 2) Северо-Западный государственный медицинский университет им. И.И. Мечникова, Санкт-Петербург, Россия; 3) Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербург, Россия
В настоящее время не существует надежных стратегий персонализации терапии больных на ранних стадиях трижды негативного рака молочной железы (ТНРМЖ). Появление ингибиторов иммунных контрольных точек в современной онкологии значительно улучшило выживаемость при некоторых онкологических заболеваниях. Новые данные свидетельствуют о том, что инфильтрирующие опухоль лимфоциты (TILs) связаны с ответом как на химиотерапию, так и на иммунотерапию пациентов с ТНРМЖ. Почему такой простой и дешевый в определении биомаркер, как TILs, не вошел в рутинную практику? Остаются проблемы, которые еще предстоит решить.

Литература


1. Keren L., Bosse M., Marquez D., et al. Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell. 2018;174(6):1373–87. e19. Doi: 10.1016/j.cell.2018.08.039.


2. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. U S A. 2001;98(19):10869–74. Doi: 10.1073/pnas.191367098.


3. Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68. Doi: 10.1186/bcr2635.


4. Lehmann B.D., Bauer J.A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67. Doi: 10.1172/JCI45014.


5. Lehmann B.D., Pietenpol J.A. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142–50. Doi: 10.1002/path.4280.


6. Lehmann B.D., Jovanovic B., Chen X., et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016;11(6):e0157368. Doi: 10.1371/journal. pone.0157368.


7. Burstein M.D., Tsimelzon A., Poage G.M., et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98. Doi: 10.1158/1078-0432.CCR-14-0432.


8. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123(1):236–40. doi: 10.1002/ijc.23518.


9. Wang M., Zhao J., Zhang L., et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761–73. Doi: 10.7150/jca.17648.


10. Семиглазов В.Ф. и др. Иммунология рака молочной железы. Под ред. В.Ф. Семиглазова. М., 2019. 204 с.


11. Loi S., Drubay D., Adams S., et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37(7):559–69. Doi: 10.1200/JCO.18.01010.


12. Tseluiko A., Semiglazov V., Kudaibergenova A., et al. The role of tumor-infiltrating lymphocytes, prognostic and predictive signification in breast cancer. Breast. 2021;56:S65. Doi: 10.1016/ S0960-9776(21)00206-X.


13. Dushyanthen S., Beavis P.A., Savas P, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13:202. Doi: 10.1186/s12916-015-0431-3.


14. Fonteneau J.F., Larsson M., Bhardwaj N. Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr Opin Immunol. 2002;14(4):471–77. Doi: 10.1016/ s0952-7915(02)00358-8.


15. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392(6671):86–9. Doi: 10.1038/32183.


16. Okcu O., Ozturk S.D., Ozturk C., et al. Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy. Ann Diagn Pathol. 2022;58:151930. Doi: 10.1016/j.anndiagpath.2022.151930.


17. Ravelli A., Roviello G., Cretella D., et al. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. Tumour Biol. 2017;39(4):1010428317695023. Doi: 10.1177/1010428317695023.


18. Wein L., Savas P., Luen S.J., et al. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Front Oncol. 2017;7:156. Doi: 10.3389/fonc.2017.00156.


19. Bense R.D., Sotiriou C., Piccart-Gebhart M.J., et al. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. J Natl Cancer Inst. 2016;109(1):djw192. Doi: 10.1093/jnci/djw192.


20. Salgado R., Denkert C., Demaria S., et al. International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71. Doi: 10.1093/annonc/ mdu450.


21. Dieci M.V., Radosevic-Robin N., Fineberg S., et al. International Immuno-Oncology Biomarker Working Group on Breast Cancer. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018;52(Pt. 2):16–25. Doi: 10.1016/j.semcancer.2017.10.003.


22. Тюляндин С.А., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли. 2021;11(3s2-1):119–57.


23. Клинические рекомендации «Рак молочной железы» Министерство здравоохранения РФ 2021 г. (пересмотр каждые 3 года).


24. Stanton S.E., Adams S., Disis M.L. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: ASystematic Review. JAMA. Oncol. 2016;2(10):1354–60. Doi: 10.1001/jamaoncol.2016.1061.


25. Garcia-Martinez E., Gil G.L., Benito A.C., et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16(6):488. Doi: 10.1186/ s13058-014-0488-5.


26. Issa-Nummer Y., Darb-Esfahani S., Loibl S., et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer -a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8(12):e79775. Doi: 10.1371/ journal.pone.0079775.


27. West N.R., Milne K., Truong P.T., et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126. Doi: 10.1186/bcr3072.


28. Gao Z.H., Li C.X., Liu M., et al. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer. 2020;20(1):1150. Doi: 10.1186/s12885-020-07654-y.


29. Costa S.D., Loibl S., Kaufmann M., et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol. 2010;28(1):83–91. Doi: 10.1200/JCO.2009.23.5101.


30. von Minckwitz G., Schneeweiss A., Loibl S., et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56. Doi: 10.1016/S1470-2045(14)70160-3.


31. Loibl S., O’Shaughnessy J., Untch M., et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497–509. Doi: 10.1016/ S1470-2045(18)30111-6.


32. Loibl S., Untch M., Burchardi N., et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–88. Doi: 10.1093/annonc/mdz158.


33. Karn T., Denkert C., Weber K.E., et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;31(9):1216–22. Doi: 10.1016/j.annonc.2020.05.015.


34. Mittendorf E.A., Zhang H., Barrios C.H., et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–100. Doi: 10.1016/ S0140-6736(20)31953-X.


35. Schmid P., Cortes J., Pusztai L., et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–21. Doi: 10.1056/ NEJMoa1910549.


36. Nanda R., Liu M.C., Yau C., et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020;6(5):676–84. Doi: 10.1001/jamaoncol.2019.6650.


37. Gianni L., Huang C.S., Egle D., et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33(5):534–43. Doi: 10.1016/j. annonc.2022.02.004.


38. de Jong V.M.T., Wang Y., Ter Hoeve N.D., et al. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. J Clin Oncol. 2022:JCO2101536. Doi: 10.1200/ JCO.21.01536.


39. Luen S.J., Salgado R., Dieci M.V., et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019;30(2):236–42. Doi: 10.1093/annonc/mdy547.


40. Dieci M.V., Criscitiello C., Goubar A., et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611– 18. Doi: 10.1093/annonc/mdt556.


41. Asano Y., Kashiwagi S., Goto W., et al. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden. BMC Cancer. 2017;17(1):888. Doi: 10.1186/s12885-017-3927-8.


42. Burstein H.J., Curigliano G., Loibl S., et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–57. Doi: 10.1093/annonc/mdz235.


43. Семиглазов В.В., Криворотько П.В., Семиглазов В.Ф. и др. Международные рекомендации по лечению рака молочной железы: руководство для врачей. Под ред. В.Ф. Семиглазова. М., 2020. 232 с.


44. Tan P.H., Ellis I., Allison K., et al. WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–85. Doi: 10.1111/his.14091.


45. Denkert C., Loibl S., Noske A., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13. Doi: 10.1200/JCO.2009.23.7370.


46. Denkert C., von Minckwitz G., Brase J.C., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–91. Doi: 10.1200/ JCO.2014.58.1967.


47. Issa-Nummer Y., Darb-Esfahani S., Loibl S., et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8(12):e79775. doi: 10.1371/ journal.pone.0079775.


48. Loibl S., Jackisch C., Schneeweiss A., et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol. 2017;28(3):497–504. Doi: 10.1093/annonc/mdw610.


49. Asano Y., Kashiwagi S., Goto W., et al. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes. Anticancer Res. 2018;38(4):2311– 21. Doi: 10.21873/anticanres.12476.


50. Filho O.M., Stover D.G., Asad S., et al. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):603–8. Doi: 10.1001/ jamaoncol.2020.7310.


Об авторах / Для корреспонденции


Автор для связи: Татьяна Юрьевна Семиглазова, д.м.н., доцент, заведующая отделом, ведущий научный сотрудник научного отдела инновационных методов терапевтической онкологии и реабилитаци, НМИЦ онкологии им. Н.Н. Петрова; профессор кафедры онкологии СЗГМУ им. И.И. Мечникова, Санкт-Петербург, Россия; tsemiglazova@mail.ru


ORCID:
Ш.Р. Абдуллаева (Sh.R. Abdullaeva), https://orcid.org/0000-0002-6601-2528
Т.Ю. Семиглазова (T.Yu. Semiglazova), https://orcid.org/0000-0002-4305-6691
А.С. Артемьева (A.S. Artemyeva), https://orcid.org/0000-0002-2948-397X
А.Г. Кудайбергенова (A.G. Kudaibergenova), https://orcid.org/0000-0001-7797-088X
С.М. Шарашенидзе (S.M. Sharashenidze), https://orcid.org/0000-0002-9842-2951
А.И. Целуйко (A.I. Tseluiko), https://orcid.org/0000-0001-8384-5786
Р.М. Палтуев (R.M. Paltuev), https://orcid.org/0000-0002-0871-9453
В.B. Семиглазов (V.V. Semiglazov), https://orcid.org/0000-0002-8825-5221
П.В. Криворотько (P.V. Krivorotko), https://orcid.org/0000-0002-4898-9159
В.Ф. Семиглазов (V.F. Semiglazov), https://orcid.org/0000-0003-0077-9619


Похожие статьи


Бионика Медиа